Allogene Therapeutics (ALLO) Operating Leases (2019 - 2025)
Historic Operating Leases for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $85.1 million.
- Allogene Therapeutics' Operating Leases fell 797.95% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year decrease of 797.95%. This contributed to the annual value of $90.8 million for FY2024, which is 458.89% down from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Operating Leases is $85.1 million, which was down 797.95% from $87.0 million recorded in Q2 2025.
- Allogene Therapeutics' 5-year Operating Leases high stood at $101.1 million for Q4 2022, and its period low was $53.9 million during Q3 2021.
- For the 5-year period, Allogene Therapeutics' Operating Leases averaged around $84.5 million, with its median value being $90.8 million (2024).
- Per our database at Business Quant, Allogene Therapeutics' Operating Leases surged by 8071.97% in 2022 and then plummeted by 797.95% in 2025.
- Over the past 5 years, Allogene Therapeutics' Operating Leases (Quarter) stood at $73.1 million in 2021, then surged by 38.28% to $101.1 million in 2022, then dropped by 5.94% to $95.1 million in 2023, then dropped by 4.59% to $90.8 million in 2024, then decreased by 6.19% to $85.1 million in 2025.
- Its Operating Leases was $85.1 million in Q3 2025, compared to $87.0 million in Q2 2025 and $88.9 million in Q1 2025.